1,2,3,4,6-Penta-O-benzoyl-D-galactopyranoside - CAS 3006-48-2
Category:
Carbohydrates
Product Name:
1,2,3,4,6-Penta-O-benzoyl-D-galactopyranoside
Synonyms:
D-Galactopyranose 1,2,3,4,6-pentabenzoate; D-Galactose, 1,2,3,4,6-pentabenzoate
CAS Number:
3006-48-2
Molecular Weight:
700.69
Molecular Formula:
C41H32O11
COA:
Inquire
MSDS:
Inquire
Structure:
Monosaccharides
Chemical Structure
CAS 3006-48-2 1,2,3,4,6-Penta-O-benzoyl-D-galactopyranoside

Related Monosaccharides Products


Reference Reading


1.Inhibition of Toll-Like Receptor 4 Signaling Mitigates Microvascular Loss but Not Fibrosis in a Model of Ischemic Acute Kidney Injury.
Dagher PC1, Hato T2, Mang HE3, Plotkin Z4, Richardson QV5, Massad M6, Mai E7, Kuehl SE8, Graham P9, Kumar R10, Sutton TA11. Int J Mol Sci. 2016 Apr 29;17(5). pii: E647.
The development of chronic kidney disease (CKD) following an episode of acute kidney injury (AKI) is an increasingly recognized clinical problem. Inhibition of toll-like receptor 4 (TLR4) protects renal function in animal models of AKI and has become a viable therapeutic strategy in AKI. However, the impact of TLR4 inhibition on the chronic sequelae of AKI is unknown. Consequently, we examined the chronic effects of TLR4 inhibition in a model of ischemic AKI. Mice with a TLR4-deletion on a C57BL/6 background and wild-type (WT) background control mice (C57BL/6) were subjected to bilateral renal artery clamping for 19 min and reperfusion for up to 6 weeks. Despite the acute protective effect of TLR4 inhibition on renal function (serum creatinine 1.6 ± 0.4 mg/dL TLR4-deletion vs. 2.8 ± 0.3 mg/dL·WT) and rates of tubular apoptosis following ischemic AKI, we found no difference in neutrophil or macrophage infiltration. Furthermore, we observed significant protection from microvascular rarefaction at six weeks following injury with TLR4-deletion, but this did not alter development of fibrosis.
2.Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.
Scheinfeld N1, Sundaram M, Teixeira H, Gu Y, Okun M. Dermatol Online J. 2016 Mar 16;22(3). pii: 13030/qt38x5922j.
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease with frequent comorbidities of painand depression. Adalimumab treatment for 16 weeks improved HS lesions significantly versus placebo (NCT00918255).OBJECTIVE: The relationship between pain and depressive symptoms and the effects of adalimumab on each was examined in this post hoc analysis.